Market revenue in 2023 | USD 1,797.7 million |
Market revenue in 2030 | USD 5,622.5 million |
Growth rate | 17.7% (CAGR from 2023 to 2030) |
Largest segment | Bioreactors/fermenters |
Fastest growing segment | Cell Culture Products |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioreactors/Fermenters, Cell Culture Products, Filters, Bioreactors Accessories, Bags & Containers |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Corning Inc, Sartorius AG, Eppendorf, Danaher Corp, Boehringer Ingelheim, Getinge AB Class B, Lonza Group Ltd, Avantor Inc, Repligen Corp, Entegris Inc, PBS Biotech, Meissner, Kuhner Shaker |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to upstream bioprocessing market will help companies and investors design strategic landscapes.
Bioreactors/fermenters was the largest segment with a revenue share of 31.22% in 2023. Horizon Databook has segmented the China upstream bioprocessing market based on bioreactors/fermenters, cell culture products, filters, bioreactors accessories, bags & containers covering the revenue growth of each sub-segment from 2018 to 2030.
There has been a robust increase in biopharmaceutical manufacturing capacity in China. As per Bio Process International, of the 25% (4.7 million liters) of active production capacity, China accounted for nearly 19% (870,000 liters) in 2019. In addition, the biopharmaceutical production capacity of CMOs has witnessed rapid growth in the country.
This can be primarily attributed to the regulatory dynamics of the country that enable third parties to develop commercial and clinical biopharmaceutical products. China has robust plans to expand manufacturing capacities and ensure faster uptake of novel technologies than other Asia Pacific countries.
In addition, strong growth of MAb therapeutics industry is anticipated to create opportunities for expansion in China’s upstream bioprocessing market. In the near future, the demand for new bioprocessing facilities is expected to significantly increase, with high demand for bioreactors having a capacity of more than 100,000 L.
Horizon Databook provides a detailed overview of country-level data and insights on the China upstream bioprocessing market , including forecasts for subscribers. This country databook contains high-level insights into China upstream bioprocessing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account